Navigation Links
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Date:8/4/2009

s adult and pediatric tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under SPA, pending commencement. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet as anticipated the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, to help generate greater interest in the market for its common stock; that the Company will be able to find suitable partners for some of its drugs under development, or raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available athttp://www.keryx.com. The information in our website is
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
2. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
3. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
5. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
6. Keryx Biopharmaceuticals Receives Nasdaq Notification
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
8. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... full benefit from breakthroughs, experts say, , , WEDNESDAY, Dec. ... currently used for research come mostly from white donors, ... that non-whites will benefit less from any medical breakthroughs ... say. , Blacks could be especially affected. In fact, ... studied showed any traces of recent African ancestry, the ...
(Date:12/16/2009)... -- Allscripts (Nasdaq: MDRX ) announced today ... the three and six months ended November 30, ... January 11, 2010. Allscripts management will host a ... earnings and other information at 8:30 AM Eastern ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second quarter ...
(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...
(Date:12/16/2009)... pinpoint seven that increase susceptibility to disease , , ... associated with increased susceptibility to leprosy have been ... The researchers, who analyzed more than 10,000 DNA ... China, said their discovery highlights the important role ... development of leprosy. , "Though leprosy is not ...
(Date:12/16/2009)... advance that could help ease health and environmental concerns ... of technology for changing the behavior of nanoparticles in ... the environment. Their study was published in ACS, journal ... from the UK Centre for Ecology and Hydrology and ... production of nanoparticles particles less than 1/1000th the ...
Breaking Medicine News(10 mins):Health News:Most Stem Cells Used in Research Come From Whites 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Leprosy Genes Identified 2Health News:Behavior modification could ease concerns about nanoparticles 2
... new survey shows that more than half (56%) of ... one-third (30%) say they would consider having cosmetic surgery ... 2009 consumer attitudes poll of 1000 American households was ... (ASAPS) and conducted by the independent research firm Synovate.Women ...
... Medical Office Building Project Provides State-of-the-Art Healthcare for ... Hampton Roads Ventures (HRV), a community development investment ... ("NMTC") program to provide equity and debt financing ... and rural communities in Virginia providing successful solutions ...
... the American Academy of Facial Plastic and Reconstructive ... and Less Expensive ProceduresNEW YORK, March 16 ... American Academy of Facial Plastic and Reconstructive Surgery ... plastic surgeons reported an increase in non-invasive cosmetic ...
... - MEDai Clients Present at the 6th Annual ... Modeling Conference - ORLANDO, Fla., March 16 ... leading provider of advanced solutions for healthcare that ... of its clients will be presenting the benefits ...
... Ships, Crew Uses BVS 5.6 Onboard Software to Navigate the ... They Bring Hope, Healing and Hospital Services to the World,s ... Technology (AWT) today announced that Mercy Ships , ... health care services to the poor, recently used the latest ...
... independent consumer advocacy group, is proud to announce ... . A respected resource for people seeking services ... SignatureForum,s new features make it easier for guests ... industry professionals and the specific services they offer. ...
Other Medicine News:Health News:Survey Finds That Women Are More Likely to Consider Plastic Surgery Than They Were Ten Years Ago, But Men Are Less Likely 2Health News:Hampton Roads Ventures Tackles U.S. Healthcare Crisis Community by Community 2Health News:New Survey Reveals 'The Lipstick Effect' With Non-Invasive Facial Plastic Surgery Procedures 2Health News:New Survey Reveals 'The Lipstick Effect' With Non-Invasive Facial Plastic Surgery Procedures 3Health News:New Survey Reveals 'The Lipstick Effect' With Non-Invasive Facial Plastic Surgery Procedures 4Health News:New Survey Reveals 'The Lipstick Effect' With Non-Invasive Facial Plastic Surgery Procedures 5Health News:Leading Healthcare Organizations Share Successes Realized with MEDai's Predictive Analytics 2Health News:Applied Weather Technology Guides Mercy Ships With Latest BVS Marine Voyage Optimization Software 2Health News:Applied Weather Technology Guides Mercy Ships With Latest BVS Marine Voyage Optimization Software 3Health News:Applied Weather Technology Guides Mercy Ships With Latest BVS Marine Voyage Optimization Software 4Health News:SignatureForum.com Relaunches with New Ratings Features 2
(Date:12/16/2009)... HDT Engineered Technologies (HDT), a leader in the ... subcontractor for the mechanical development of the Modular ... arm technology that will give patients improved, dexterous ... a sense of touch. ,, As part ... Revolutionizing Prosthetics 2009 (RP2009) project, the MPL overcomes ...
(Date:12/16/2009)... A new application developed by American ... of specialty pharmaceuticals has increased health plan staff ... reducing costs. ,, AIM, a leading diagnostic imaging ... clients representing over 35 million consumers and an ... WLP ), adapted the successful clinical and technology ...
(Date:12/16/2009)... Wis., Dec. 16 EuroPharma, Inc. ... for the use of super absorbency BCM-95® ... EuroPharma formulations. The exclusive distribution territory ... health food store channel and professional channel, ... and clinics. BCM-95® is a highly ...
Breaking Medicine Technology:HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3Instrumentation Laboratory Installs 2000th ACL TOP 28R 29 System 5144 1Instrumentation Laboratory Installs 2000th ACL TOP 28R 29 System 5144 2Instrumentation Laboratory Installs 2000th ACL TOP 28R 29 System 5144 3SyntheMed Completes 241 0 Million Equity Placement 5140 1SyntheMed Completes 241 0 Million Equity Placement 5140 2Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting 5136 1Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting 5136 2Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting 5136 3Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting 5136 4
... throughput reading of entire racks. Its scanner-based image ... and reads in approximately 10 seconds per rack. ... and a list of ActiveX controls is provided ... includes a USB HP Scanner and software. Compatible ...
... with powder-coated steel legs. Height ... in hundreds of sizes and ... light fixtures and ionizing equipment. ... custom building to meet special ...
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... This BioSafe room is configured specifically ... and chemical analysis. Panels are precision-joined ... easy to wipe down and disinfect. ... double-wall panel design creates strong, rigid ...
Medicine Products: